Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Brug af en blodprøve og et softwareværktøj til at guide behandlingen af venøs tromboemboli

6. november 2026 opdateret af: Memorial Sloan Kettering Cancer Center

Et ikke-randomiseret forsøg ved brug af DNA væske-biopsier til at styre antikoagulation for patienter med cancer-relateret tromboemboli

The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

259

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Justin Jee, MD, PhD
  • Telefonnummer: 646-608-4409
  • E-mail: jeej@mskcc.org

Studiesteder

      • Sydney, Australien, 2065
        • Ikke rekrutterer endnu
        • Royal North Shore Hospital, Australia
        • Kontakt:
          • Adrian Lee, MBBS, FRACP PhD
          • Telefonnummer: 02 8037 4100
    • New Jersey
      • Basking Ridge, New Jersey, Forenede Stater, 07920
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities)
        • Kontakt:
          • Justin Jee, MD, PhD
          • Telefonnummer: 646-608-4409
      • Middletown, New Jersey, Forenede Stater, 07748
        • Rekruttering
        • Memorial Sloan Kettering Monmouth (All Protocol Activities)
        • Kontakt:
          • Justin Jee, MD, PhD
          • Telefonnummer: 646-608-4409
      • Montvale, New Jersey, Forenede Stater, 07645
        • Rekruttering
        • Memorial Sloan Kettering Bergen (All Protocol Activities)
        • Kontakt:
          • Justin Jee, MD, PhD
          • Telefonnummer: 646-608-4409
    • New York
      • Commack, New York, Forenede Stater, 11725
        • Rekruttering
        • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
        • Kontakt:
          • Justin Jee, MD, PhD
          • Telefonnummer: 646-608-4409
      • Harrison, New York, Forenede Stater, 10604
        • Rekruttering
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
        • Kontakt:
          • Justin Jee, MD, PhD
          • Telefonnummer: 646-608-4409
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center (All Protocol Activites)
        • Kontakt:
          • Justin Jee, MD, PhD
          • Telefonnummer: 646-608-4409
      • Rockville Centre, New York, Forenede Stater, 11553
        • Rekruttering
        • Memorial Sloan Kettering Nassau (All protocol activities)
        • Kontakt:
          • Justin Jee, MD, PhD
          • Telefonnummer: 646-608-4409

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 with a history of cancer-associated VTE (objectively confirmed symptomatic or incidental/unsuspected proximal lower-limb DVT, symptomatic pulmonary embolism [PE] or incidental PE in a segmental or more proximal pulmonary artery) and completion of between 3 and 12 months of anticoagulation with enoxaparin, dalteparin,rivaroxaban, or apixaban without current VTE-related symptoms (imaging to confirm resolution not required).

Diagnosis of DVT requires evidence of one or more filling defects at compression ultrasonography, venography, CT venography, or MR venography involving at least the popliteal or more proximal veins.

Diagnosis of PE requires an intraluminal filling defect in segmental or more proximal arteries.

  • Diagnosis of one of the following solid tumors in either advanced (i.e. unresectable) stage or receiving systemic anticancer treatment within six weeks of enrollment (maintenance therapy included):

    • breast cancer regardless of cytotoxic-chemotherapy status
    • hepatobiliary cancer regardless of cytotoxic-chemotherapy status
    • prostate cancer regardless of cytotoxic-chemotherapy status
    • non-small cell lung cancer with cytotoxic-chemotherapy received within 30 days
    • pancreatic cancer with cytotoxic-chemotherapy received within 30 days
    • bladder cancer with cytotoxic-chemotherapy received within 30 days
  • Signed and dated informed consent by study participant/Legally Authorized Representative (LAR).

Exclusion Criteria:

  • Contraindication to ongoing anticoagulation
  • Contraindication to discontinuation of anticoagulation (examples include but not limited to: known antiphospholipid syndrome or factor V leiden, active arterial thrombus, catheter-associated thrombus, on anticoagulation for atrial fibrillation or other non-oncologic reasons)
  • History of major bleeding in the last six months (major bleeding defined as fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; bleeding that necessitates acute surgical intervention; bleeding causing a fall in hemoglobin levels of 1.24 mmol/L (2 g/dL or greater) or more; or bleeding leading to a transfusion of 2 U or more of whole blood or red cells).
  • Known diagnosis of disseminated intravascular coagulation (DIC)
  • Suspicion for tumor thrombus on the imaging leading to original diagnosis of VTE
  • Enrolled in hospice care
  • Currently has inferior vena cava (IVC) filter
  • Diagnosis of an active hematologic malignancy

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: High risk for recurrent Venous Thromboembolism/VTE

Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk.

MSK-ACCESS is a ctDNA sequencing assay

Machine learning Venous Thromboembolism/VTE risk score mode

Eksperimentel: Low-risk for recurrent Venous Thromboembolism/VTE

Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk.

MSK-ACCESS is a ctDNA sequencing assay

Machine learning Venous Thromboembolism/VTE risk score mode

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cumulative incidence of recurrent Venous Thromboembolism/VTE
Tidsramme: 6 months

Evaluate the cumulative incidence of recurrent Venous Thromboembolism/VTE at 6 months following discontinuation of anticoagulation in participants with low risk DNA liquid biopsy-based model.

6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Justine Jee, MD, PhD, Memorial Sloan Kettering Cancer Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. januar 2026

Primær færdiggørelse (Anslået)

30. januar 2030

Studieafslutning (Anslået)

30. januar 2030

Datoer for studieregistrering

Først indsendt

3. februar 2026

Først indsendt, der opfyldte QC-kriterier

3. februar 2026

Først opslået (Faktiske)

10. februar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner